Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Other Non-Current Liabilities: 2013-2025

Historic Other Non-Current Liabilities for Fortress Biotech (FBIO) over the last 12 years, with Sep 2025 value amounting to $1.6 million.

  • Fortress Biotech's Other Non-Current Liabilities fell 7.82% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 7.82%. This contributed to the annual value of $1.8 million for FY2024, which is 7.24% down from last year.
  • Fortress Biotech's Other Non-Current Liabilities amounted to $1.6 million in Q3 2025, which was down 2.77% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's Other Non-Current Liabilities registered a high of $4.4 million during Q3 2021, and its lowest value of $1.6 million during Q3 2025.
  • Its 3-year average for Other Non-Current Liabilities is $1.8 million, with a median of $1.8 million in 2023.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first tumbled by 73.68% in 2021, then grew by 4.36% in 2022.
  • Over the past 5 years, Fortress Biotech's Other Non-Current Liabilities (Quarterly) stood at $2.0 million in 2021, then fell by 9.15% to $1.8 million in 2022, then rose by 2.49% to $1.9 million in 2023, then dropped by 7.24% to $1.8 million in 2024, then fell by 7.82% to $1.6 million in 2025.
  • Its Other Non-Current Liabilities stands at $1.6 million for Q3 2025, versus $1.7 million for Q2 2025 and $1.7 million for Q1 2025.